Abnormal Regulation of DNA Methyltransferase Expression during Colorectal Carcinogenesis

Angelo M. De Marzo, Valerie L. Marchi, Eddy S. Yang, Ravi Veeraswamy, Xiaohui Lin, and William G. Nelson

Abstract

Somatic changes in CpG dinucleotide methylation occur quite commonly in human cancer cell DNA. Relative to DNA from normal human colonic cells, DNA from human colorectal cancer cells typically displays regional CpG dinucleotide hypermethylation amid global CpG dinucleotide hypomethylation. The role of the maintenance DNA methyltransferase (DNMT1) in the acquisition of such abnormal CpG dinucleotide methylation changes in colorectal cancer cells remains controversial; in one study, 60–200-fold increases in DNMT1 mRNA expression were detected in colorectal polyps and cancers relative to normal colonic tissue [W. S. El-Deiry et al., Proc. Natl. Acad. Sci. USA, 88: 3470–3474, 1991], whereas in another study, only small increases in DNMT1 mRNA expression, commensurate with differences in cell proliferation accompanying colonic tumorigenesis, were observed [P. J. Lee et al., Proc. Natl. Acad. Sci. USA, 92: 10366–10370, 1996]. To definitively ascertain whether abnormal DNMT1 expression might accompany human colorectal carcinogenesis, we subjected a series of normal and neoplastic colonic tissues to immunohistochemical staining using a polyclonal antiserum raised against a DNMT1 polypeptide. A concordance of DNMT1 expression with the expression of PCNA and other cell proliferation markers, such as Ki-67 and DNA topoisomerase IIα, was observed in normal colonic epithelial cells and in cells comprising other normal epithelia and lymphoid tissues. The polypeptide p21, which has been reported to undermine DNMT1 binding to proliferating cell nuclear antigen at DNA replication sites, was not expressed by normal colonic cells containing DNMT1 and other cell proliferation markers. In adenomatous polyps, although DNMT1 expression coincided with the expression of other cell proliferation markers, many DNMT1-expressing cells also expressed p21. The fidelity of DNMT1 expression was further undermined in colorectal carcinomas, in which a striking heterogeneity in DNMT1 expression, with some carcinoma cells containing very low DNMT1 levels, and others containing very low DNMT1 levels, was observed. These results indicate that human colorectal carcinogenesis is accompanied by a progressive dysregulation of DNMT1 expression and suggest that abnormalities in DNMT1 expression may contribute to the abnormal CpG dinucleotide methylation changes characteristic of human colorectal carcinoma cell DNA.

Introduction

Although most self-complementary CpG dinucleotides in mammalian genomic DNA carry 5-mC in place of C, clusters of unmethylated CpG dinucleotides, termed “CpG islands,” encompass the transcriptional regulatory regions of many genes (1). In normal somatic cells, the precise patterns of CpG dinucleotide methylation in the genome can be maintained with fidelity through DNA replication and mitosis via the action of a maintenance DNA methyltransferase. However, human cancer cells typically contain DNA with abnormal CpG dinucleotide methylation patterns (2–4). Most often, cancer cell DNA exhibits increases in CpG dinucleotide methylation at certain specific CpG island sequences, accompanied by generalized decreases in CpG dinucleotide methylation at most other sites. Such alterations in DNA methylation can lead to changes in gene function subject to selection during neoplastic transformation and malignant progression, e.g., CpG island DNA methylation changes can result in gene inactivation via a silencing of gene transcription.

How do cancer cells acquire abnormal CpG dinucleotide methylation patterns? One mechanistic hypothesis focuses on a malfunctioning of the DNA methyltransferase DNMT1. Tumorigenic cells have long been known to have high DNA methyltransferase levels (5). In in vitro model systems, overexpression of DNA methyltransferases has been shown to cause increased CpG dinucleotide methylation (6) and to trigger transformation (7, 8). Recently, increased DNA methyltransferase expression was demonstrated to be an essential molecular step in c-fos-mediated transformation in vitro (9). DNA methyltransferase activity may also be essential for transformation in vivo; mice carrying defective Apc genes at high risk for developing colonic adenomas develop fewer polyps when carrying disrupted alleles for Dnmt1, a gene encoding a DNA methyltransferase likely capable of both maintenance and de novo CpG dinucleotide methylation (10, 11). Recent data have also provided a clue as to how decreased methylation of CpG dinucleotides might occur, despite the expression or overexpression of a DNA methyltransferase (12). To carry out its maintenance DNA methylation function, DNMT1 must be recruited to sites of DNA replication by binding to PCNA3 (13–15). Chuang et al. (12) have reported that the cell cycle regulatory polypeptide p21 disrupts DNMT1 binding to PCNA. Perhaps, if p21 is inappropriately expressed or induced by DNA damage or other stress, maintenance DNA methylation activity may be disrupted (16).

DNA methylation changes, including generalized CpG dinucleotide hypomethylation and specific CpG island hypermethylation, stereotypically accompany human colorectal carcinogenesis (17–23). El-Deiry et al. (24) reported that increases in DNMT1 mRNA expression also tended to accompany colorectal carcinogenesis. When compared with DNMT1 levels present in normal colonic epithelium, using a reverse transcription-PCR assay technique, as much as a 60-fold increase in DNMT1 mRNA was detected in adenomatous polypl lesions, and as much as a 200-fold increase in DNMT1 mRNA was detected in carcinoma lesions. In a follow-up study, more modest increases in DNA methyltransferase activity in colonic neoplasms versus normal colonic epithelium were noted (25). Lee et al. (26) subsequently disputed these findings. Using an

Received 5/3/99; accepted 6/30/99.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

3This work was supported by NB/National Cancer Institute Grants CA 9236 and CAT 0196.

To whom requests for reprints should be addressed, at The Brady Urological Institute, Marburg 411, The Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287. Phone: (410) 614-1661; Fax: (410) 614-3695.

3The abbreviation used is: PCNA, proliferating cell nuclear antigen.
RNase protection technique targeting a different region of \(DNMT1\) mRNA, only slight increases in \(DNMT1\) mRNA levels in colonic neoplasms, commensurate with increases in cell proliferation, were observed. To definitively ascertain whether abnormal \(DNMT1\) expression might accompany human colorectal carcinogenesis, we subjected a series of normal and neoplastic colonic tissues to immunohistochemical staining for DNMT1 polypeptides. We report here that human colorectal carcinogenesis is accompanied by a progressive dysregulation of DNMT1 expression and propose that abnormalities in DNMT1 expression likely contribute to the abnormal CpG dinucleotide methylation changes characteristic of human colorectal carcinoma cell DNA.

**Materials and Methods**

**Normal and Neoplastic Colonic Tissues.** Normal and neoplastic formalin-fixed, paraffin-embedded tissues were obtained from the surgical pathology archives of the Johns Hopkins Hospital. Specimens of normal colonic tissue, colonic adenoma tissue, and invasive colonic carcinoma tissue were removed at colectomy for colorectal cancer or at endoscopy for colorectal polyps. Other normal tissues, including specimens of tonsil, uterine cervix, stomach, and small intestine, were also removed as part of surgical procedures. At the time of removal, all tissue specimens were immediately immersed in 10% neutral buffered formalin and subsequently embedded into paraffin blocks. Additional tonsil tissue was snap frozen and subsequently stored at −70°C for protein extraction (see below).

**Immunohistochemical Staining.** For immunohistochemical staining analyses, tissue sections cut from the paraffin blocks were first deparaffinized and rehydrated and subjected to specific antibody staining for various antigens using the Biotek Techmate 1000 robotic immunostainer (Ventana Medical Systems, Tuscon, AZ). All primary antibody incubations were conducted at room temperature for 45 min; biotinylated secondary antibody incubations were carried out at room temperature for 30 min. Histochemical localization was accomplished using avidin-biotin horseradish peroxidase complex (Vectastain ABC; Vector Laboratories, Incorporated, Burlingame, CA) with 3,3′-diaminobenzidine tetrahydrochloride as the chromagen. After immunohistochemical staining, tissue sections were counterstained with hematoxylin.

**Immunoblot Analysis.** Total protein extracts were prepared from frozen (−70°C) human tonsil tissue and from HCT-116 human colorectal adenocarcinoma cells propagated in vitro in McCoy’s growth medium supplemented...
with 10% FCS (Life Technologies, Inc., Gaithersburg, MD). Protein extraction was accomplished by homogenization at 4°C in a lysis buffer containing 1% NP40, 150 mM NaCl, and 1 mM EDTA in 50 mM Tris-HCl at pH 7.5 supplemented with a protease inhibitor mixture that included 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml E64, and 100 µg/ml phenylmethylsulfonyl fluoride (Sigma Chemical Co., St. Louis, MO). The resultant homogenates were clarified by centrifugation at 10,000 rpm in a Beckman microfuge for 10 min, and the protein extract supernatants were stored at −70°C. The protein concentration of each extract was estimated using the BCA assay (Pierce, Rockford, IL). For immunoblot analysis, protein extracts were electrophoresed on 6.5% polyacrylamide gels in the presence of SDS and then transferred to nitrocellulose filters (Amersham Pharmacia Biotech, Inc., Piscataway, NJ) electrophoretically. The nitrocellulose membrane blots were then treated with a blocking solution (5% nonfat dry milk and 0.05% Tween 20 in TBS) overnight at 4°C before being exposed to anti-DNMT1 antibodies at a concentration of 2 µg/ml in 5% nonfat dry milk and 0.05% Tween 20 in TBS for 2 h at room temperature. After extensive washing with TBS containing 0.05% Tween 20, the anti-DNMT1 antibodies were detected using horseradish peroxidase-conjugated anti-rabbit antibodies (Amersham Pharmacia Biotech) and a chemiluminescence substrate (SuperSignal West Pico chemiluminescence substrate; Pierce) in a manner similar to that described previously (28). Alternatively, SDS-polyacrylamide gels containing electrophoretically separated protein extracts were stained with Coomassie blue (Sigma).

Results and Discussion

Previous data have suggested a tight coupling between normal somatic cell proliferation and DNA methyltransferase expression (13, 14, 29–32). Analysis of Dnmt1 expression and activity in mouse 3T3 cells has demonstrated that as growth-arrested cells are stimulated to progress from G0 into S-phase, an increase in Dnmt1 mRNA levels and Dnmt enzyme activity occurs (30). However, nuclear run-on transcription assays suggested that Dnmt1 was transcribed in both growth-arrested and growth-stimulated cells, indicating that the proliferation-dependent increases in Dnmt1

Fig. 2. Immunohistochemical staining for DNMT1 in human tonsil tissue. Lymphoid cells in germinal centers and basal epithelial cells in respiratory epithelium expressed significant levels of DNMT1. Similar staining patterns were observed using antibodies directed against PCNA, Ki-67, and topoisomerase IIa.

DNA METHYLTRANSFERASE DURING COLORRECTAL CARCINOGENESIS

3857

Downloaded from cancerres.aacrjournals.org on April 15, 2017. © 1999 American Association for Cancer Research.
mRNA levels were likely the result of a posttranscriptional mechanism, such as differential mRNA stability (30). Perhaps because DNMT1 mRNA abundance may be subject to active mRNA degradation, two independent studies of DNMT1 mRNA levels in normal and neoplastic human colonic tissues, using assays targeting different regions of the DNMT1 mRNA template, yielded remarkably different results (24, 26).

For our study, we used antibodies raised against a human DNMT1-derived polypeptide to directly detect the enzyme in normal and neoplastic cells and tissues. When the antibodies were used for immunoblot analysis of protein extracts from normal tonsil tissue and from HCT-116 colonic carcinoma cells propagated in vitro, a single polypeptide of $M_r \approx 190,000$ was detected in each extract (Fig. 1). When the same antibodies were used in immunohistochemical staining studies of a variety of normal tissues, including tonsil (Fig. 2), respiratory epithelium (Fig. 2), uterine cervix, stomach, small intestine, and colon (Fig. 3), a tight concordance of DNMT1 expression with the expression of PCNA was evident. A fraction of cells in the colon that appeared to express DNMT1 and PCNA also expressed other DNA proliferation markers such as Ki-67 (27) and DNA topoisomerase IIa (Refs. 33 and 34; not shown).

Analysis of DNMT1 expression in normal colonic epithelium also disclosed that the crypt epithelial cells that expressed DNMT1 and PCNA did not express p21, whereas the noncrypt epithelial cells, which tended not to express DNMT1 or other cell proliferation markers, expressed high levels of p21 (Fig. 3). In adenomatous polyps, Wu et al. (35) have reported abnormal p21 expression in cells expressing markers of proliferation such as Ki-67. In our study, we also found abnormal coexpression of p21 and proliferative markers in adenomatous polyps. Furthermore, many cells comprising adenomatous polyps appeared to express both DNMT1 and p21 (Fig. 4). A possible consequence of the coexpression of DNMT1 and p21 in proliferating colonic polyp cells may be an undermining of maintenance DNA methyltransferase activity, via p21 disruption of DNMT1 and PCNA interactions at replication foci (12–14), that might lead to global hypomethylation. Occasional cells in colonic polyps expressing DNMT1 appeared also to contain slightly higher levels of the enzyme than normal crypt cells expressing DNMT1 in adjacent colonic mucosa. This elevated expression of DNMT1 in these rare adenoma cells might tend to lead to hypermethylation of some regions of adenoma cell DNA (6).

DNMT1 expression in colorectal carcinomas appeared strikingly abnormal (Fig. 5). Carcinoma cells exhibiting very high and very low levels of immunohistochemical staining for DNMT1 levels present in the same cancer tissue were detected. In addition, p21 also appeared to be haphazardly expressed (not shown). Clearly, the dysregulated expression of DNMT1 in colorectal carcinoma cells could result in a dysregulation of the fidelity of CpG dinucleotide methylation, with cells expressing low levels of DNMT1 or coexpressing DNMT1 and p21 prone to hypomethylation and cells expressing high levels of DNMT1 prone to hypermethylation. In any case, all of the DNMT1 immunohistochemistry data collected for this study revealed that a progressive dysregulation of DNMT1 expression appeared to accompany colorectal carcinogenesis (Fig. 6).

Maintenance of the fidelity of CpG dinucleotide methylation patterns through DNA replication likely requires the tightly regulated expression of a maintenance methyltransferase in replicating cells and the tightly controlled function of the enzyme near the DNA replication fork (15). We propose that dysregulation of DNMT1 expression, such as that seen during human colorectal carcinogenesis, might lead to inadequate maintenance of normal CpG dinucleotide methylation patterns and to abnormal de novo methylation changes. Although the mechanisms by which the control of DNMT1 expression becomes altered in neoplastic colorectal carcinoma cells have not been identified, studies of the mouse Dnmt1 regulation have suggested that ras signaling may trigger transcriptional activation (36, 37). Further insights into the normal and abnormal regulation of Dnmt1 and DNMT1 await more precise definition and characterization of the gene regulatory region (38).
Our finding of a progressive dysregulation of DNMT1 expression accompanying colorectal carcinogenesis supports the general set of mechanistic hypotheses that emphasize a malfunctioning of a maintenance DNA methyltransferase in the acquisition of abnormal CpG dinucleotide patterns characteristic of neoplastic transformation and malignant progression. Maintenance methyltransferase malfunction may not be the only mechanism by which abnormal CpG dinucleotide methylation occurs in cancer cells, however. The recent identification of additional mammalian DNA methyltransferases (39), capable of de novo CpG dinucleotide methylation in vitro, and of a mammalian 5-mCpG demethylase (40), capable of reducing CpG dinucleotide methylation in vivo, offers additional possible mechanistic explanations for the acquisition of abnormal CpG dinucleotide methylation changes in cancer cells as well. Abnormal regulation of additional de novo DNA methyltransferases and of 5-mCpG demethylases in neoplastic cells could only further undermine the fidelity of CpG dinucleotide pattern maintenance.
DNA METHYLTRANSFERASE DURING COLORECTAL CARCINOGENESIS


Acknowledgments

We thank Drs. Steven B. Baylin, Donald S. Coffey, William B. Isaacs, and Jonathan W. Simons for critical reading of the manuscript and helpful comments, and we thank Kimberly Heaney for help in preparing the manuscript for submission.

References


Abnormal Regulation of DNA Methyltransferase Expression during Colorectal Carcinogenesis

Angelo M. De Marzo, Valerie L. Marchi, Eddy S. Yang, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/59/16/3855

Cited articles
This article cites 40 articles, 25 of which you can access for free at:
http://cancerres.aacrjournals.org/content/59/16/3855.full.html#ref-list-1

Citing articles
This article has been cited by 34 HighWire-hosted articles. Access the articles at:
/content/59/16/3855.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.